Trial Profile
Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary) ; Sirolimus
- Indications Angiomyolipoma; Gastrointestinal stromal tumours; Giant cell tumour of tendon sheath; Leiomyosarcoma; Meningioma; Nerve sheath neoplasms; Sarcoma; Soft tissue sarcoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms PLX3397
- 12 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.
- 12 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Feb 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Jul 2023.